BridgeBio Pharma, Inc. Comprehensive Income
BridgeBio Pharma, Inc. (BBIO) reported Comprehensive Income of -$152.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-10
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$152.22M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$164.06M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$192.85M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$182.74M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$724.93M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$535.78M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$642.84M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$481.38M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$152.22M 10-Q · filed 2026-08-10 | -$316.28M 10-Q · filed 2026-08-10 | -$509.13M derived: sum of 3 quarters · filed 2026-08-10 | -$691.87M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$164.06M 10-Q · filed 2026-05-07 | -$356.92M derived: sum of 2 quarters · filed 2026-05-07 | -$539.66M derived: sum of 3 quarters · filed 2026-05-07 | -$721.56M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$192.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$375.60M derived: sum of 2 quarters · filed 2026-02-24 | -$557.50M derived: sum of 3 quarters · filed 2026-08-10 | -$724.93M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | -$182.74M 10-Q · filed 2025-10-29 | -$364.64M derived: sum of 2 quarters · filed 2026-08-10 | -$532.07M 10-Q · filed 2025-10-29 | -$797.12M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$181.90M 10-Q · filed 2026-08-10 | -$349.33M 10-Q · filed 2026-08-10 | -$614.38M derived: sum of 3 quarters · filed 2026-08-10 | -$776.41M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$167.43M 10-Q · filed 2026-05-07 | -$432.48M derived: sum of 2 quarters · filed 2026-05-07 | -$594.51M derived: sum of 3 quarters · filed 2026-05-07 | -$667.97M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$265.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$427.08M derived: sum of 2 quarters · filed 2026-02-24 | -$500.54M derived: sum of 3 quarters · filed 2026-02-24 | -$535.78M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$162.03M 10-Q · filed 2025-10-29 | -$235.49M derived: sum of 2 quarters · filed 2025-10-29 | -$270.74M 10-Q · filed 2025-10-29 | -$438.89M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | -$73.46M 10-Q · filed 2025-08-05 | -$108.71M 10-Q · filed 2025-08-05 | -$276.86M derived: sum of 3 quarters · filed 2026-02-24 | -$453.89M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | -$35.24M 10-Q · filed 2025-04-29 | -$203.40M derived: sum of 2 quarters · filed 2026-02-24 | -$380.42M derived: sum of 3 quarters · filed 2026-02-24 | -$538.25M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | -$168.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$345.18M derived: sum of 2 quarters · filed 2026-02-24 | -$503.00M derived: sum of 3 quarters · filed 2026-02-24 | -$642.84M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | -$177.03M 10-Q · filed 2024-11-12 | -$334.85M derived: sum of 2 quarters · filed 2024-11-12 | -$474.69M 10-Q · filed 2024-11-12 | -$612.26M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-06-30 | -$157.82M 10-Q · filed 2024-08-01 | -$297.66M 10-Q · filed 2024-08-01 | -$435.24M derived: sum of 3 quarters · filed 2025-02-20 | -$572.50M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-03-31 | -$139.84M 10-Q · filed 2024-05-02 | -$277.41M derived: sum of 2 quarters · filed 2025-02-20 | -$414.67M derived: sum of 3 quarters · filed 2025-02-20 | -$424.57M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2022-12-31 | -$137.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$274.83M derived: sum of 2 quarters · filed 2025-02-20 | -$284.73M derived: sum of 3 quarters · filed 2025-02-20 | -$481.38M 10-K · filed 2025-02-20 | ||
| 2022-09-30 | -$137.26M 10-Q · filed 2023-11-02 | -$147.16M derived: sum of 2 quarters · filed 2023-11-02 | -$343.81M 10-Q · filed 2023-11-02 | -$491.14M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | -$9.90M 10-Q · filed 2023-08-03 | -$206.55M 10-Q · filed 2023-08-03 | -$353.88M derived: sum of 3 quarters · filed 2024-02-22 | -$509.83M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | -$196.65M 10-Q · filed 2023-05-04 | -$343.98M derived: sum of 2 quarters · filed 2024-02-22 | -$499.93M derived: sum of 3 quarters · filed 2024-02-22 | -$596.18M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | -$147.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$303.28M derived: sum of 2 quarters · filed 2024-02-22 | -$399.54M derived: sum of 3 quarters · filed 2024-02-22 | -$562.86M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | -$155.95M 10-Q · filed 2022-11-03 | -$252.21M derived: sum of 2 quarters · filed 2022-11-03 | -$415.54M 10-Q · filed 2022-11-03 | -$535.78M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | -$96.25M 10-Q · filed 2022-08-04 | -$259.58M 10-Q · filed 2022-08-04 | -$379.83M derived: sum of 3 quarters · filed 2023-02-23 | -$496.09M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | -$163.33M 10-Q · filed 2022-05-05 | -$283.58M derived: sum of 2 quarters · filed 2023-02-23 | -$399.83M derived: sum of 3 quarters · filed 2023-02-23 | -$520.74M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | -$120.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$236.51M derived: sum of 2 quarters · filed 2023-02-23 | -$357.41M derived: sum of 3 quarters · filed 2023-02-23 | -$448.79M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | -$116.26M 10-Q · filed 2021-11-04 | -$237.16M derived: sum of 2 quarters · filed 2021-11-04 | -$328.54M 10-Q · filed 2021-11-04 | -$401.89M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | -$120.90M 10-Q · filed 2021-08-05 | -$212.28M 10-Q · filed 2021-08-05 | -$285.64M derived: sum of 3 quarters · filed 2022-02-25 | -$345.46M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | -$91.38M 10-Q · filed 2021-05-06 | -$164.73M derived: sum of 2 quarters · filed 2022-02-25 | -$224.56M derived: sum of 3 quarters · filed 2022-02-25 | -$290.53M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2019-12-31 | -$73.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$133.18M derived: sum of 2 quarters · filed 2022-02-25 | -$199.15M derived: sum of 3 quarters · filed 2022-02-25 | -$260.33M 10-K · filed 2022-02-25 | ||
| 2019-09-30 | -$59.83M 10-Q · filed 2020-11-05 | -$60.51M 10-Q · filed 2019-11-08 | -$125.79M derived: sum of 2 quarters · filed 2020-11-05 | -$186.98M 10-Q · filed 2020-11-05 | -$204.28M 10-Q · filed 2019-11-08 | -$197.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$65.96M 10-Q · filed 2020-08-11 | -$127.15M 10-Q · filed 2020-08-11 | -$137.69M derived: sum of 3 quarters · filed 2021-02-25 | -$179.77M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | -$61.19M 10-Q · filed 2020-05-14 | -$71.72M derived: sum of 2 quarters · filed 2021-02-25 | -$113.80M derived: sum of 3 quarters · filed 2021-02-25 | |||
| 2018-12-31 | -$10.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$52.62M derived: sum of 2 quarters · filed 2021-02-25 | -$130.75M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$42.08M 10-Q · filed 2019-11-08 | -$120.21M 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | -$30.57M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |